Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03326245|
Recruitment Status : Recruiting
First Posted : October 31, 2017
Last Update Posted : January 11, 2022
Dopamine (DA) is a chemical signal in the brain linked to learning, memory, and habits. Stimulant drugs like methylphenidate can increase DA in the brain. Researchers want to measure DA with and without this drug. They want to learn how methylphenidate and brain dopamine affect body responses, mood, and thinking.
To better understand the role of dopamine in the brain and the effects of methylphenidate.
Adults ages 18-55 who have used alcohol or stimulant drugs but have no drug dependence.
Participants will be screened with:
- Physical exam
- Question about medical, psychiatric, and alcohol and drug use history
- Questions to see if it s safe to have a PET/MRI scan
- Blood and urine tests
- Breath test for alcohol
Participants will have 3 or 4 study visits. At each visit they will have:
- Urine and breath tested for alcohol and drugs
- A thin plastic tube (catheter) inserted in each arm by needle
- A small amount of radioactive chemical injected through the catheter.
- PET/MRI scan. Participants will lie still on a table that slides in and out of a metal cylinder surrounded by a strong magnetic field. Their vital signs will be monitored. They will get earmuffs for loud noises. Before the scan, participants will get the study drug or placebo through the catheter. They may also get a sugar pill (placebo). They will get a small meal and have blood drawn.
- Tests of memory, attention, and thinking.
Participants will wear an activity monitor on the wrist for one week.
|Condition or disease||Intervention/treatment||Phase|
|Normal Physiology||Drug: Oral Methylphenidate followed by IV placebo Drug: Oral placebo followed by IV Methylphenidate Drug: Oral Placebo followed by IV Placebo||Phase 1|
Objectives: The overarching goal of this study is to assess the dynamic association between dopamine (DA) D2 receptor (D2R) occupancy measured by positron emission tomography (PET) with [11C]raclopride and brain activity inferred by pharmacological magnetic resonance imaging (phMRI) in the human brain, and to assess the relative sensitivity and specificity of the neurovascular coupling for slow (oral) versus rapid (intravenous, IV) stimulant methylphenidate (MP) delivery. Secondary objectives are to assess the associations between behavioral measures (heart and respiration rates and blood pressure, motor and sleep parameters, and neuropsychological testing variables), D2R occupancy and fMRI signals.
Study population: 10 healthy males and 10 healthy females 18-55 years old will be included. Test-retest reproducibility studies will be carried out in 5 participants.
Design: Double-blind. Participants will undergo simultaneous PET/phMRI, to evaluate dynamic changes in D2R occupancy by DA with [11C]raclopride and in blood-oxygenation-level dependent (BOLD) signals, under MP or placebo (PL). The participants will be scanned on 3 different occasions: 1) oral-MP (60 mg) and iv PL (3 cc saline), 2) oral-PL and iv-MP (0.25 mg/kg in 3 cc sterile water) and 3) oral PL and iv PL, which will be carried in different study days with at least 48 hours between them and their order will be randomized across subjects. Participants and researchers will be blind to the nature of the stimulant drug (MP/PL).
Outcome parameters: The scale factor between the distribution volume ratio (DVR) and the BOLD signal in the dorsal and ventral striatum for the slow and fast MP challenges.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI|
|Actual Study Start Date :||January 29, 2018|
|Estimated Primary Completion Date :||December 31, 2024|
|Estimated Study Completion Date :||December 31, 2025|
Active Comparator: 1:Oral MP- IV PL
Oral Methylphenidate /IV Placebo
Drug: Oral Methylphenidate followed by IV placebo
Oral MP (60 mg) will be given 30 minutes prior to bolus [11C]raclopride injection followed by iv placebo (PL) given 30 minutes post bolus injection of [11C]raclopride.
Active Comparator: 2 Oral PL/IV MP
Oral Placebo/IV Methylphenidate
Drug: Oral placebo followed by IV Methylphenidate
Oral PL will be given 30 minutes prior to bolus [11C]raclopride injection followed by iv MP (0.25 mg/kg) given 30 minutes post bolus injection of [11C]raclopride.
Placebo Comparator: 3: Oral PL/IV PL
Oral Placebo/IV Placebo
Drug: Oral Placebo followed by IV Placebo
Oral PL will be given 30 minutes prior to bolus [11C]raclopride injection followed by iv PL given 30 minutes post bolus injection of [11C]raclopride.
- To assess the scale factor between the distribution volume ratio (DVR) and the BOLD signal in the dorsal and ventral striatum for the slow and fast MP challenges. [ Time Frame: end of study ]To assess the distribution volume ratios (DVR), the %BOLD signal change after MP (oral and iv), the %DVR change after MP (oral and iv), and the temporal correlation between BOLD(t) and DVR(t).
- Pupil size, Eye Blinks, HR, BP, Respiration Rate [ Time Frame: end of study ]To assess the correlation between BOLD(t) and behavioral measures (pupil size, eye blinks, heart rate, blood pressure, and respiration rate).
- Heart rate, BP, Respiration Rate [ Time Frame: end of study ]To assess the correlation between DVR(t) and behavioral measures (heart rate, BP, and respiration rate).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03326245
|Contact: Dardo G Tomasi, Ph.D.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 firstname.lastname@example.org|
|Principal Investigator:||Dardo G Tomasi, Ph.D.||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|